- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11.24 | Eupraxia Pharmaceuticals Inc: Eupraxia talks DiffuSphere PK data from studies | 6 | Stockwatch | ||
| 20.11.24 | Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months | 1 | CNW | ||
| 14.11.24 | Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting | 1 | CNW | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.11.24 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11.24 | Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 | 1 | CNW | ||
| 13.11.24 | Eupraxia Pharmaceuticals Inc: Eupraxia releases data from cohort 5 of Resolve trial | 2 | Stockwatch | ||
| 12.11.24 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis | 88 | PR Newswire | One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.
Consistent improvement in patient-reported outcomes with six of six evaluable... ► Artikel lesen | |
| 07.11.24 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results | 119 | PR Newswire | VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology... ► Artikel lesen | |
| 07.11.24 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.11.24 | Eupraxia Pharmaceuticals Inc: Eupraxia closes $44.52-million private placement | 1 | Stockwatch | ||
| 01.11.24 | Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million | 2 | CNW | ||
| 28.10.24 | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
| 28.10.24 | Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 | 3 | CNW | ||
| 28.10.24 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.10.24 | Eupraxia Pharmaceuticals Inc: Eupraxia's EP-104IAR trial data published in Lancet | 3 | Stockwatch | ||
| 15.10.24 | Eupraxia reports Phase 2b trial success for osteoarthritis treatment | 1 | Investing.com | ||
| 15.10.24 | Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis | 1 | CNW | ||
| 10.10.24 | Eupraxia Pharmaceuticals reports to SEC on latest developments | 1 | Investing.com | ||
| 10.10.24 | Eupraxia Pharmaceuticals reicht Bericht bei der SEC ein | 3 | Investing.com Deutsch | ||
| 10.10.24 | Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 | 1 | CNW |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
| TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
| 89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
| IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| QIAGEN | 42,945 | +0,10 % | Biotech Report: Evotec fest, Qiagen gehen leichter ins Wochenende | (shareribs.com) Frankfurt / New York 24.01.2025 - Biotech-Aktien tendieren am Freitag uneinheitlich. Für Qiagen geht es abwärts, während Evotec zulegen kann. An der Wall Street kann der Sektor zulegen.... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
| AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,450 | -1,16 % | Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What Happened | ||
| VALNEVA | 2,744 | +10,11 % | Commerzbank, Deutsche Bank, Evotec, Infineon, Nvidia, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 30,310 | -1,43 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
EUPRAXIA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,39 % bei einem Aktienkurs von 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
